Lantheus Holdings, Inc. is engaged in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products, which assist clinicians in the diagnosis of cardiovascular and other diseases. The Company�s agents are used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. Clinicians use its imaging agents and products across a range of imaging modalities, including nuclear imaging, echocardiography and magnetic resonance imaging (MRI). The Company�s commercial products are used by nuclear physicians, cardiologists, radiologists, internal medicine physicians, technologists and sonographers working in a range of clinical settings. The Company�s commercial products are DEFINITY and TechneLite. Its portfolio of commercial products also includes imaging agents in specific market segments, which provide a stable base of recurring revenue.